Jeffrey Wager, M.D.
Chairman & CEOjeff.email@example.com
Between 2011-2017, co-creator and BOD observer to Grupo Biotoscana SL, a Latin American specialty pharma roll-up financed by Advent International and Essex Woodlands Healthcare Ventures focused on cancer, infectious and rare diseases, leading to its USD 1 billion 2017 IPO on sales of ~$240M and 600 staff in 10 LatAm markets.
From 2006 – 2010, formed and led Artisan Pharma, Inc. as its founding CEO, raising $53M, building the entire team and implementing a 750 patient, 17 country Phase 2b/3 study ultimately leading to Artisan’s acquisition by Asahi Kasei Pharma Corporation (Japan) in 2011.
In 2000, formed Apeiron Partners, a FINRA-registered life sciences investment bank focused on corporate spin-outs, M+A, corporate venture capital and principal investments. In the process, successfully completed six spin-outs, including Targacept, Inc. (NASD:TRGT), Artisan Pharma (from Asahi Kasei), Biocritica ($120M annual revenue Xigris® franchise from Eli Lilly) and KBI BioPharma (from KBI). Between 2003 and 2006, advised on the establishment and investment of Z-Cube s.r.l., the €60M corporate venture fund of the Zambon Group, a €700M privately-held Italian pharmaceutical company.
Between 1995-2000, Dr. Wager was with Medical Science Partners, a Harvard-sponsored VC fund focused on forming spin-outs from the Harvard medical system, including deCODE, ICAgen, Inspire, Oravax (subsequently Acambis), ZYCOS, Inc. and Diatide, amongst others.
Dr. Wager began his career with a life sciences unit of the Bank of Tokyo, where he led business development, responsible for helping Japanese pharmaceutical clients establish overseas affiliates, design and implement overseas clinical development and structure strategic alliances.
Dr. Wager is also a co-founder and Chairman of Proterris, Inc., a P2/3 clinical-stage firm focused on therapeutic uses of low-dose gaseous and small molecule carbon monoxide for transplant, fibrosis, and oncology indications.
Dr. Wager earned his MD from Rush Medical College and his MBA from the University of Chicago.
Jeffrey Wager, M.D.
Chairman & CEO
Acting Chief Financial Officerstephan.wehselau(at)enbiotix.com
Stephan is a serial entrepreneur with over 20 years' C-level experience as CFO and CEO, having raised over $300 million in venture capital and private equity from high-profile international venture capital and private equity funds in the US, Europe and Asia in the life sciences & IT industries. He has negotiated several major loan financings totaling $60M, and has a long track record in deal making including M&A, strategic alliances and corporate deals.
He was previously founding CFO of JenaValve Technology Inc. a medical device company in USA and Germany, and raised one of the largest VC rounds ever for a medical device company in Europe ($72.5M). He was a co-founder of Xantos AG, a well-known drug development company in Munich, in the field of oncology and diabetes in 1999, and co-founder of Spherotec GmbH a diagnostic company in Munich, Germany in the field of personalized medicine for cancer. He started his career in the pharma industry and worked first for Boehringer Mannheim and later on for Roche. Beside his management roles he was co-founder and non-executive Board member of NascaCell AG, SpheroTec GmbH, Tube Pharmaceuticals GmbH, eZono AG and Opsyon i.G. Stephan is also co-founder and CEO/CFO of the new established Munich based ImmuCon GmbH a drug development company developing new treatments in inflammatory and autoimmune diseases.
In the IT space, Stephan was CFO of censhare AG, a software company from 2015 – 2018 where he raised significant capital and had a significant influence on the strong growth path of the company in this period.
Acting Chief Financial Officer
Benjamin Perrone, Ph.D.
Director, Business Development & Financeben.perrone(at)enbiotix-dot-com
Benjamin Perrone has over ten years of biomedical research, development, and translation experience. Before joining EnBiotix, he worked as Senior Associate, New Ventures in the Boston University Office of Technology Development, where he helped spin out six NewCos built around Boston University technologies in the life sciences, med tech, and healthcare I.T. spaces, and built a new application and evaluation process for the Ignition gap funding award program, with templates later incorporated by the BU Coulter Foundation Award and by the NSF SBIR program.
He is also a Program Leader at the Boston chapter of the Startup Leadership Program, an angel-sponsored training program for outstanding startup founders and innovators, and splits his free time between kite-surfing and bridge. He received his Ph.D. in Biomedical Engineering from Boston University, and a B.A. with Honors in Physics from the University of Chicago.
Benjamin Perrone, Ph.D.
Director, Business Development & Finance
Diane Joseph-McCarthy, Ph.D.
R&D Advisor, Anti-Persisters, Phage & LPA Programsdiane.j-m(at)enbiotix-dot-com
Diane Joseph-McCarthy is Senior Vice President, Discovery and Early Development at EnBiotix, with more than 20 years drug discovery and leadership experience in the pharmaceutical and biotechnology sector. Before joining EnBiotix, she was an Associate Director in the Infection iMED at AstraZeneca, where she led an innovative group of scientists as well as a global team in Predictive Science. Dr. Joseph-McCarthy was also part of several task forces aimed at transforming Infection’s early portfolio. Prior to that she was at Wyeth where she held positions of increasing responsibility. She has been actively involved in the discovery of several compounds that have reached clinical trials. Dr. Joseph-McCarthy received her PhD from MIT and was a postdoctoral fellow at Harvard University and Harvard Medical School. She has more than 70 publications/patents and has given numerous invited talks. She also has served as a member of the National Academy of Sciences Polio Antiviral Advisory Committee as well as editorial advisory boards for international journals.